Dengue Fever - Pipeline Insight, 2024

This “Dengue Fever - Pipeline Insight, 2024,” report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Dengue Fever pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Dengue Fever Understanding

Dengue Fever: Overview

Dengue Virus (DENV) is an arbovirus (arthropod-borne virus). Four serotypes of DENV are responsible for the infectious disease called dengue that annually affects nearly 400 million people worldwide. Dengue fever is a common mosquito-borne illness in many tropical and subtropical countries. Classic dengue fever, or “break bone fever,” is characterized by acute onset of high fever 3-14 days after the bite of an infected mosquito. Some patients with dengue fever go on to develop dengue hemorrhagic fever (DHF), a severe and sometimes fatal form of the disease. Millions of cases of dengue infection occur worldwide each year. Dengue fever is most common in Southeast Asia, the western Pacific islands, Latin America and Africa. Severe dengue fever happens when blood vessels become damaged and leaky. And the number of clot-forming cells (platelets) in bloodstream drops. This can lead to shock, internal bleeding, organ failure and even death.

Symptoms
Dengue fever causes a high fever - 104 F (40 C) - and any of the following signs and symptoms:

• Headache
• Muscle, bone or joint pain
• Nausea
• Vomiting
• Pain behind the eyes
• Swollen glands
• Rash

Diagnosis
The diagnosis of Dengue fever is made by identifying the type of dengue virus and the symptoms associated. Unequivocal diagnosis of dengue infection requires laboratory confirmation, either by isolating the virus or detecting dengue-specific antibodies, Serological testing, Nucleic acid amplification test, and others.

Treatment
The goal of treatment is to manage symptoms and keep the infection from becoming more severe. In areas of the world where dengue fever is common, one dengue fever vaccine (Dengvaxia) is approved for people ages 9 to 45 who have already had dengue fever at least once. The vaccine is given in three doses over the course of 12 months. The World Health Organization stresses that the vaccine is not an effective tool on its own to reduce dengue fever in areas where the illness is common. Preventing mosquito bites and controlling the mosquito population are still the main methods for preventing the spread of dengue fever.

Dengue Fever Emerging Drugs Chapters

This segment of the Dengue Fever report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Dengue Fever Emerging Drugs

TAK003: Takeda Takeda's TAK-003 is an investigational live-attenuated tetravalent dengue vaccine, preventing dengue fever caused by any of the four serotypes of the dengue virus of which can cause dengue fever or Severe Dengue. Takeda’s current clinical development program consists of five Phase 3 trials of TAK003 Clinical Phase 1 and 2 data in children and adolescents showed that TAK-003 induced immune responses against all four dengueserotypes.

V180: Merck Sharp & Dohme Merck & Co's adjuvanted, tetravalent subunit vaccine V180 comprises truncated forms of envelope proteins (DEN-80E), derived from strains of all four dengue virus serotypes. The DEN-80E subunits are expressed from plasmids in the Drosophila S2 cell expression system and are formulated with either ISCOMATRIX and Alhydrogel.V180's more compact dosing schedule could make it a more attractive alternative to Dengvaxia, particularly for travelers. However, its current three-dose schedule could still be improved to reduce the risk of non-compliance. It is believed that V180 would achieve its greatest commercial potential as part of a heterologous prime-boost strategy with TetraVax-DV. V180 is currently in Phase I development.

AV1: Ab Viro LLCAV-1 is a human monoclonal antibody (mAb) being investigated as a potential therapy for dengue, a mosquito-borne viral disease with extensive global public health impact. Currently Av1 is being studied in phase I in adult healthyindividuals.

Dengue Fever: Therapeutic Assessment

This segment of the report provides insights about the different Dengue Fever drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Dengue Fever

There are approx. 10+ key companies which are developing the therapies for Dengue Fever. The companies which have their Dengue Fever drug candidates in the mid to advanced stage, i.e. phase III and Phase II include, Takeda and others.

Phases

This report covers around 10+ products under different phases of clinical development like

• Late-stage products (Phase III)
• Early-stage products (Phase I/II and Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

Route of Administration

Dengue Fever pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Subcutaneous
• Intravenous
• Intramuscular
• Molecule Type

Products have been categorized under various Molecule types such as

• Small molecules
• Proteins
• Monoclonal antibodies
• Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Dengue Fever: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Dengue Fever therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Dengue Fever drugs.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Dengue Fever R&D. The therapies under development are focused on novel approaches to treat/improve Dengue Fever.

Dengue Fever Report Insights

• Dengue Fever Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Dengue Fever Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Dengue Fever drugs?
• How many Dengue Fever drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Dengue Fever?
• What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Dengue Fever therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Dengue Fever and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• Emergex Vaccines
• Abivax
• Takeda
• Merck Sharp & Dohme
• Immunoforge
• Chugai Pharmaceutical Co., Ltd.
• Codagenix
• Biotron Ltd
• GlaxoSmithKline
• Ennaid therapeutics
• Ab ViroLLC
• Medigen Vaccine Biologics Corp.

Key Products

• TAK003
• V180
• DENV Vaccine
• AV1
• TAK003
• TV003

This product will be delivered within 2 business days.